5 Results for "

PD-1 checkpoint blockade

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "PD-1 checkpoint blockade" in MCE Product Catalog:

Cat. No.: HY-163844
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC50 of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint .
loading...
    loading...
Cat. No.: HY-L266
101 compounds

PD-1/PD-L1 signaling is a central negative regulatory axis that maintains immune homeostasis. It involves the specific binding of PD-1 to its ligands PD-L1/PD-L2 and the subsequent transduction of inhibitory signals, which suppress T cell activation and proliferation, drive T cell exhaustion, and contribute to tumor immune evasion. Dysregulation of this pathway is closely linked to major diseases including cancer, chronic viral infections, autoimmune disorders, and transplant rejection. Immune checkpoint blockade targeting PD-1/PD-L1 has emerged as a leading frontier in cancer therapy and mechanistic research.

The MCE PD-1 Compound Library contains 101 structurally defined small molecules, covering modulators related to the PD-1/PD-L1 signaling pathway. It can be used for cancer immunotherapy research, studies of immune resistance mechanisms, and candidate compound screening, providing chemical tools for immune checkpoint mechanism research, drug discovery, and high-throughput screening.

Cat. No.: HY-184119
CAS No.: 3061276-55-6
Synonyms: IM502
Pabgraminone C (IM502) is a Fungal metabolite and PI3Kγ inhibitor with an IC50 of 61.7 nM against PI3Kγ. Pabgraminone C shifts the STAT signaling pathway in cells from an immunosuppressive STAT3/STAT6-dominant profile to an immunostimulatory STAT1/STAT2-dominant profile, driving cells toward a pro-inflammatory phenotype. Pabgraminone C reprograms cells from an immunosuppressive state to an immunostimulatory state, reversing their suppressive effect on anti-tumor immunity. Pabgraminone C inhibits established tumor growth and metastasis across multiple cancer types. Pabgraminone C overcomes resistance to PD-1 checkpoint blockade strategies. Pabgraminone C can be used in research related to liver cancer, melanoma, and colorectal cancer .
loading...
    loading...
Cat. No.: HY-184203
Target:  

HDAC

Research Areas:  

Cancer

SM-06-09 is a potent, highly selective, orally active tetrazolone-based HDAC6 inhibitor with an IC50 value of 0.49 nM. SM-06-09 promotes tumor-associated macrophage (TAM) polarization toward an antitumor M1-like phenotype and enhances macrophage phagocytosis, antigen presentation, and T-cell activation. SM-06-09 remodels the tumor immune microenvironment, exhibits antitumor activity in melanoma models, and enhances the efficacy of anti-PD-1 immune checkpoint blockade .
loading...
    loading...
Cat. No.: HY-189364
CAS No.: 88262-44-6
Synonyms: SMC247-9
Research Areas:  

Cancer

(DL)-3,5-Dimethyltyrosine (SMC247-9) is a selective APOBEC3B inhibitor optimized from SMC247, with an IC50 of 50 pM. (DL)-3,5-Dimethyltyrosine binds to the APOBEC3B protein, reduces intracellular APOBEC3B protein abundance partially through a lysosome-dependent pathway, enhances IL-15 expression in tumor cells, and relieves the suppression of CD8 + T cells by tumor cells in an IL-15-dependent manner. (DL)-3,5-Dimethyltyrosine attenuates tumor- and macrophage-derived chemokine-mediated macrophage chemotaxis and inhibits pathological myeloid inflammatory signaling. (DL)-3,5-Dimethyltyrosine inhibits tumor growth in the immune checkpoint blockade-responsive MC38 syngeneic mouse model and produces synergistic effects with anti-PD-L1 in the immune checkpoint blockade-resistant TC-1 tumor model; it also ameliorates anti-PD-1-exacerbated DSS-induced colitis-like intestinal inflammatory injury. (DL)-3,5-Dimethyltyrosine can be used in research related to tumor immunotherapy .
loading...
    loading...